Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA
Authors:
Open Access
- 1 October 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (19) , 9636-9645
Abstract
By deciphering the dysregulation of apoptosis in melanoma cells, new treatment approaches exploiting aberrant control mechanisms regulating cell death can be envisioned. Among the Bcl-2 family, a BH3-only member, NOXA, functions in a specific mitochondrial-based cell death pathway when melanoma cells are exposed to a proteasome inhibitor (e.g., bortezomib). Some therapeutic agents, such as bortezomib, not only induce proapoptotic Bcl-2 family members and active conformational changes in Bak and Bax but also are associated with undesirable effects, including accumulation of antiapoptotic proteins, such as Mcl-1. To enhance the bortezomib-mediated killing of melanoma cells, the apoptotic pathway involving NOXA was further investigated, leading to identification of an important target (i.e., the labile Bcl-2 homologue Mcl-1 but not other survival proteins). To reduce Mcl-1 levels, melanoma cells were pretreated with several different agents, including Mcl-1 small interfering RNA (siRNA), UV light, or the purine nucleoside analogue fludarabine. By simultaneously triggering production of NOXA (using bortezomib) as well as reducing Mcl-1 levels (using siRNA, UV light, or fludarabine), significantly enhanced killing of melanoma cells was achieved. These results show binding interactions between distinct Bcl-2 family members, such as NOXA and Mcl-1, in melanoma cells, paving the way for novel and rational therapeutic combination strategies, which target guardians of the proapoptotic Bak- and Bax-mediated pathways, against this highly aggressive and often fatal malignancy. (Cancer Res 2006; 66(19): 9636-45)Keywords
This publication has 56 references indexed in Scilit:
- Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic ImplicationsCancer Research, 2005
- Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma CellsCancer Research, 2005
- Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-xL reduction thereby enhancing UV-light induced apoptosisOncogene, 2005
- BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis: Figure 1.Genes & Development, 2005
- Cell DeathCell, 2004
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- Activation of Bak, Bax, and BH3-only Proteins in the Apoptotic Response to DoxorubicinJournal of Biological Chemistry, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999